Limitations of Chromogranin A in clinical practice

References

• Borges R, Díaz-Vera J, Domínguez N, Arnau MR, Machado JD. (2010). Chromogranins as regulators of exocytosis. J Neurochem 114:335–343.
   PubMed Web of Science ®Google Scholar
• Campana D, Nori F, Piscitelli L, Morselli-Labate AM, Pezzilli R, Corinaldesi R, Tomassetti P. (2007). Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol 25:1967–1973.
   PubMed Web of Science ®Google Scholar
• de Bruïne AP, Wiggers T, Beek C, Volovics A, von Meyenfeldt M, Arends JW, Bosman FT. (1993). Endocrine cells in colorectal adenocarcinomas: incidence, hormone profile and prognostic relevance. Int J Cancer 54:765–771.
   PubMed Web of Science ®Google Scholar
• Edge SB, Byrd DR, Compton CC, et al. (2010). 7th edition AJCC Cancer Staging Manual. New York, NY: Springer.
   Google Scholar
• Faggiano A, Sabourin JC, Ducreux M, Lumbroso J, Duvillard P, Leboulleux S, Dromain C, Colao A, Schlumberger M, Baudin E. (2007). Pulmonary and extrapulmonary poorly differentiated large cell neuroendocrine carcinomas: diagnostic and prognostic features. Cancer 110:265–274.
   PubMed Web of Science ®Google Scholar
• Ferolla P, Faggiano A, Mansueto G, Avenia N, Cantelmi MG, Giovenali P, Del Basso De Caro ML, Milone F, Scarpelli G, Masone S, Santeusanio F, Lombardi G, Angeletti G, Colao A. (2008). The biological characterization of neuroendocrine tumors: the role of neuroendocrine markers. J Endocrinol Invest 31:277–286.
   PubMed Web of Science ®Google Scholar
• Glinicki P, Jeske W. (2010). Chromogranin A (CgA)–the influence of various factors in vivo and in vitro, and existing disorders on it’s concentration in blood. Endokrynol Pol 61:384–387.
   PubMed Web of Science ®Google Scholar
• Goebel SU, Serrano J, Yu F, Gibril F, Venzon DJ, Jensen RT. (1999). Prospective study of the value of serum chromogranin A or serum gastrin levels in the assessment of the presence, extent, or growth of gastrinomas. Cancer 85:1470–1483.
   PubMed Web of Science ®Google Scholar
• Granberg D, Stridsberg M, Seensalu R, Eriksson B, Lundqvist G, Oberg K, Skogseid B. (1999). Plasma chromogranin A in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 84:2712–2717.
   PubMed Web of Science ®Google Scholar
• Guignat L, Bidart JM, Nocera M, Comoy E, Schlumberger M, Baudin E. (2001). Chromogranin A and the alpha-subunit of glycoprotein hormones in medullary thyroid carcinoma and phaeochromocytoma. Br J Cancer 84:808–812.
   PubMed Web of Science ®Google Scholar
• Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. (2010). The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 39:707–712.
   PubMed Web of Science ®Google Scholar
• Klöppel G, Solcia E, Capella C, Heitz PU. (1999). Classification of neuroendocrine tumours. Ital J Gastroenterol Hepatol 31 Suppl 2:S111–S116.
   PubMedGoogle Scholar
• Kuipers EJ. (2006). Proton pump inhibitors and gastric neoplasia. Gut 55:1217–1221.
   PubMed Web of Science ®Google Scholar
• Milione M, Seregni E. (2010). Pathological diagnosis and tumor markers. Tumori 96:810–816.
   PubMed Web of Science ®Google Scholar
• Nobels FR, Kwekkeboom DJ, Coopmans W, Hoekstra R, De Herder WW, Bouillon R, Lamberts SW. (1993). A comparison between the diagnostic value of gonadotropins, alpha-subunit, and chromogranin-A and their response to thyrotropin-releasing hormone in clinically nonfunctioning, alpha-subunit-secreting, and gonadotroph pituitary adenomas. J Clin Endocrinol Metab 77:784–789.
   PubMed Web of Science ®Google Scholar
• Nobels FR, Kwekkeboom DJ, Coopmans W, Schoenmakers CH, Lindemans J, De Herder WW, Krenning EP, Bouillon R, Lamberts SW. (1997). Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab 82:2622–2628.
   PubMed Web of Science ®Google Scholar
• O’Connor DT, Pandlan MR, Carlton E, Cervenka JH, Hslao RJ. (1989). Rapid radioimmunoassay of circulating chromogranin A: in vitro stability, exploration of the neuroendocrine character of neoplasia, and assessment of the effects of organ failure. Clin Chem 35:1631–1637.
   PubMed Web of Science ®Google Scholar
• O’Toole D, Grossman A, Gross D, Delle Fave G, Barkmanova J, O’Connor J, Pape UF, Plöckinger U; Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society. (2009). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers. Neuroendocrinology 90:194–202.
   PubMed Web of Science ®Google Scholar
• Scopsi L, Andreola S, Pilotti S, Testori A, Baldini MT, Leoni F, Lombardi L, Hutton JC, Shimizu F, Rosa P. (1992). Argyrophilia and granin (chromogranin/secretogranin) expression in female breast carcinomas. Their relationship to survival and other disease parameters. Am J Surg Pathol 16:561–576.
   PubMed Web of Science ®Google Scholar
• Seregni E, Ferrari L, Bajetta E, Martinetti A, Bombardieri E. (2001). Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. Ann Oncol 12 Suppl 2:S69–S72.
   PubMed Web of Science ®Google Scholar
• Solcia E, Kloppel G, Sobin LH et al. (2000). Histological Typing of Endocrine Tumours (World Health Organization. International Classification of Tumours) 2nd edn. Heidelberg: Springer-Verlag.
   Google Scholar
• Sundaresan V, Reeve JG, Stenning S, Stewart S, Bleehen NM. (1991). Neuroendocrine differentiation and clinical behaviour in non-small cell lung tumours. Br J Cancer 64:333–338.
   PubMed Web of Science ®Google Scholar
• Takiyyuddin MA, Cervenka JH, Hsiao RJ, Barbosa JA, Parmer RJ, O’Connor DT. (1990). Chromogranin A. Storage and release in hypertension. Hypertension 15:237–246.
   PubMed Web of Science ®Google Scholar
• Takiyyuddin MA, Parmer RJ, Kailasam MT, Cervenka JH, Kennedy B, Ziegler MG, Lin MC, Li J, Grim CE, Wright FA. (1995). Chromogranin A in human hypertension. Influence of heredity. Hypertension 26:213–220.
   PubMed Web of Science ®Google Scholar
• Vezzosi D, Walter T, Laplanche A, Raoul JL, Dromain C, Ruszniewski P, d’Herbomez M, Guigay J, Mitry E, Cadiot G, Leboulleux S, Lombard-Bohas C, Borson-Chazot F, Ducreux M, Baudin E. (2011). Chromogranin A measurement in metastatic well-differentiated gastroenteropancreatic neuroendocrine carcinoma: screening for false positives and a prospective follow-up study. Int J Biol Markers 26:94–101.
   PubMed Web of Science ®Google Scholar
• Zatelli MC, Torta M, Leon A, Ambrosio MR, Gion M, Tomassetti P, De Braud F, Delle Fave G, Dogliotti L, degli Uberti EC; Italian CromaNet Working Group. (2007). Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. Endocr Relat Cancer 14:473–482.
   PubMed Web of Science ®Google Scholar